Clinical Trials · NCT00946920
A Trial of Degarelix in Patients With Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 859
- Start date
- Jun 2009
- Locations
- 126 sites, 14 countries
- Primary endpoint
- Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) With Degarelix